kenvue is wellpositioned for accelerated growth following its separation from parent company johnson  johnson according to jpmorgan following its spinoff earlier in may kenvue is the largest pureplay consumer health company in the world the company holds commonlyknown brands such as neutrogena tylenol aveeno and zyrtec amounting to 10 brands with sales greater than 400 million kenvue also has over 37 regional brands analyst andrea teixeira initiated coverage on the stock with an overweight rating her price target of 29 implies 1026 upside from the previous close as a standalone company we believe kenvue board and management will be more focused and accountable for the growth and profitability of the business following the separation that began in 2019 with significant opportunities to scale in many adjacencies and markets around the world organically and through tuckin m  a texeira wrote in a monday note we view kvue as uniquely positioned to benefit from consumer mega trends selfcare aging teixeira added that kenvue still is uscentric giving it room to regain share and lift and shift some of its brands in overseas markets jpmorgan thinks kenvue is still trading at an attractive valuation despite jumping since its may 3 ipo which was priced at 22 per share shares were at 2630 through fridays close as kvue builds its track record as a public company if our estimates for solid quarters ahead materialize and postpotential distribution of shares that jnj owns to current jnj shareholders we believe kvue should trade with the majorleague highquality multinationals that have defensive sales compounding growth and solid free cash flow conversion said teixeira —cnbcs michael bloom contributed to this report